![[Valid Atom 1.0]](images/valid-atom.png "Valid Atom 1.0")
This is a valid Atom 1.0 feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom"> <id>https://ijpcr.net/ijpcr/issue/feed</id> <title>International Journal of Pharmacology and Clinical Research (IJPCR)</title> <updated>2025-09-18T05:17:21+00:00</updated> <author> <name>Dr.N.Sriram</name> <email>ijpcreditor@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr" /> <link rel="self" type="application/atom+xml" href="https://ijpcr.net/ijpcr/feed/atom" /> <generator uri="http://pkp.sfu.ca/ojs/" version="3.1.2.4">Open Journal Systems</generator> <subtitle type="html"><p><strong><em>International Journal of Pharmacology and Clinical Research (IJPCR) </em></strong>is a peer-reviewed, quarterly official international journal allowing access to abstracts<strong>&nbsp;</strong>and<strong>&nbsp;</strong>full-text. The journal is devoted to the promotion of pharmaceutical sciences and related disciplines (Pharmacology, Biopharmaceutics, Pharmacokinetics, Pharmaceutical Medicinal Chemistry, Computational Chemistry &amp; Molecular Drug Design, Pharmacognosy &amp; Phytochemistry, Pharmaceutical Analysis, Pharmacy Practice, Clinical &amp; Hospital Pharmacy, Cell Biology, Genomics &amp; Proteomics, Pharmacogenomics, Bioinformatics including biotechnology, cell &amp; molecular biology, Pharmaceutical biotechnology/microbiology, medical and other life sciences).</p> <p><strong>ISSN</strong>&nbsp;-&nbsp;<strong><em>International Journal of Pharmacology and Clinical Research (IJPCR)</em></strong></p> <p><strong>Online</strong>:<strong>&nbsp;</strong>2521-2206</p> <p><strong><em>International Journal of Pharmacology and Clinical Research </em></strong>seeks to foster multidisciplinary research and collaboration among scientists, pharmaceutical industries and healthcare sector as well as provide an international forum for the communication and evaluation of data, methods and opinions in pharmaceutical sciences and related disciplines. Although primarily devoted to original research papers, the journal particularly welcomes reviews on current topics of special interest and relevance. All manuscripts will be subjected to rapid peer review. Those of high quality (not previously published and not already under consideration for publication) will be published.</p></subtitle> <entry> <id>https://ijpcr.net/ijpcr/article/view/629</id> <title>Neuropharmacology</title> <updated>2025-09-18T05:17:21+00:00</updated> <author> <name>Nampelly Raaziiv Varma</name> <email>nampellyraaziivvarma@gmail.com</email> </author> <author> <name>Tajuddin Shaik</name> <email>nampellyraaziivvarma@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/629" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/629"><p>Neuropharmacology studies the effects of drugs on the nervous system's cellular function and how neurons communicate. The focus is on developing drugs to treat neurological disorders like pain, neurodegenerative diseases, psychological disorders, and addiction. Understanding human behaviour and thought processes is crucial for neuropharmacology to advance medicine. This article discusses behavioural and molecular neuropharmacology, specifically the direct receptors, ion channels, and neurotransmitters that drug actions manipulate. The blood-brain barrier is a significant obstacle to drug delivery, but advances in nanotechnology are creating novel approaches to improve drug delivery for neurological disorders. Nanoscale drug delivery systems like exosomes, liposomes, polymeric nanoparticles, and aptamer-conjugated nanoparticles have shown to increase brain penetration, improve drug efficacy, and decrease systemic toxicity. However, challenges such as scalability, regulatory challenges, and immunogenicity remain.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></summary> <published>2025-07-01T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/676</id> <title>Bronchitis as a Component of COPD: Overlapping Symptoms, Diagnosis, and Management Approaches</title> <updated>2025-08-01T14:45:09+00:00</updated> <author> <name>M.R. Vinayakamurthi</name> <email>pvagals@gmail.com</email> </author> <author> <name>P.V. Agalya Gayathri</name> <email>pvagals@gmail.com</email> </author> <author> <name>S. Nandhini</name> <email>pvagals@gmail.com</email> </author> <author> <name>M. Navaneetha Krishnan</name> <email>pvagals@gmail.com</email> </author> <author> <name>G. Subitcha Jabakani</name> <email>pvagals@gmail.com</email> </author> <author> <name>B. Yuvankarthik</name> <email>pvagals@gmail.com</email> </author> <author> <name>M. Nithya Kalyani</name> <email>pvagals@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/676" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/676"><p>Bronchitis, a common respiratory disorder, encompasses both acute and chronic forms and significantly contributes to global respiratory disease burden. Acute, usually viral bronchitis presents with a productive cough and often resolves without antibiotics, though overtreatment remains common. Chronic bronchitis, a subtype of Chronic Obstructive Pulmonary Disease (COPD), results from long-term exposure to irritants like cigarette smoke and environmental pollutants. It is characterized by persistent cough, mucus overproduction, and progressive airflow obstruction due to chronic airway inflammation and structural changes. Diagnosis involves clinical evaluation, spirometry, imaging, and sputum analysis. Management includes smoking cessation, bronchodilators, oxygen therapy, and antibiotics during exacerbations. Preventive strategies such as vaccination and reducing pollutant exposure are essential. Emerging research focuses on precision medicine and minimally invasive interventions like targeted lung denervation and bronchial rheoplasty, aiming to minimize mucus hypersecretion and improve outcomes. Future directions also include biomarker-driven treatment, regenerative therapies, and digital tools for disease monitoring and self-management</p></summary> <published>2025-08-01T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> <entry> <id>https://ijpcr.net/ijpcr/article/view/677</id> <title>A New Era in Medical Care with Pharmacogenomics in Personalized Medicine</title> <updated>2025-08-08T10:05:27+00:00</updated> <author> <name>Suresh S</name> <email>suresh17gfed@gmail.com</email> </author> <author> <name>Karpagam Kumara Sundari. S</name> <email>suresh17gfed@gmail.com</email> </author> <link rel="alternate" href="https://ijpcr.net/ijpcr/article/view/677" /> <summary type="html" xml:base="https://ijpcr.net/ijpcr/article/view/677"><p>Pharmaceutical corporations have increasingly used genomic data to choose therapeutic targets and develop precision medicine strategies. Most large pharmaceutical corporations regularly conduct pharmacogenomic (PGx) investigations and collect DNA from clinical trial participants. Artificial intelligence-driven analytics, high-throughput "-omics" platforms, and recent advancements in genomics are undermining the conventional "one-size-fits-all" therapy paradigm and opening the door to really customized medicine. This review looks at how personalized medicine has evolved from early observations of differences in how people respond to medications to today's complex models that use data from pharmacogenomics, proteomics, metabolomics, and transcriptomics. We talk about how liquid biopsies, wearable biosensors, CRISPR-mediated genome editing, and next-generation sequencing advance our understanding of disease processes, patient stratification, and precision dosing. HER2 amplification and other companion diagnostics in cancer, as well as pharmacogenomic indicators from the cytochrome P450 superfamily (CYP2D6, CYP2C19, and CYP3A5), have changed treatment regimens. In translational science, psychiatry, and cardiology, we look into new applications. We also examine emerging applications in translational science, psychiatry, and cardiology, showing that machine-learning models trained on multi-modal datasets are more accurate than cohort-based methods at predicting long-term outcomes, toxicity, and efficacy. We conclude by examining the challenges of execution, ethics, and legislation that need to be resolved before customized medicine can fully become a part of standard care. These include fair access, pricing, professional education, and data protection. By bringing these diverse threads together, the essay provides a thorough overview of the current state of tailored medicine and a roadmap for its broad clinical adoption.</p></summary> <published>2025-08-08T00:00:00+00:00</published> <rights>Copyright (c) </rights> </entry> </feed> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid Atom 1.0" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
